Avai Bio (AVAI) Common Equity (2018 - 2026)

Avai Bio (AVAI) has 9 years of Common Equity data on file, last reported at -$2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 80.01% year-over-year to -$2.8 million; the trailing twelve-month figure through Mar 2026 stood at -$2.8 million (down 80.01% YoY), and the FY2026 full-year result was -$2.8 million, down 80.01% from the prior year.
• Common Equity fell to -$2.8 million in Q1 2026, from -$2.8 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.1 million in Q4 2024 to a low of -$2.8 million in Q1 2026.
• A 5-year average of -$993529.6 and a median of -$993781.0 in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 754.19% in 2022 and surged 283.14% in 2024, its largest moves.
• Tracing AVAI's Common Equity over 5 years: stood at -$539482.0 in 2022, then slumped by 159.67% to -$1.4 million in 2023, then soared by 252.45% to $2.1 million in 2024, then plunged by 230.85% to -$2.8 million in 2025, then retreated by 0.74% to -$2.8 million in 2026.
• Business Quant data shows AVAI's Common Equity at -$2.8 million in Q1 2026, -$2.8 million in Q4 2025, and -$2.3 million in Q3 2025.